contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-in-scandinavian-real-heart-ab-publ-on-16-december-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Scandinavian Real Heart operates in the medical technology sector. The company conducts research and development in observations of the physiology of the heart. The development of the company's product, a complete artificial heart, is taking place in collaboration with cardiac surgeons, researchers and engineers. The focus is on developing patented solutions that can imitate the blood circulation of the natural human heart, with the goal of being used by patients diagnosed with heart failure. The company was founded in 2007.

Scandinavian Real Heart

Scandinavian Real Heart AB (publ) held an Extraordinary General Meeting on December 16, 2025. All decisions were made in accordance with the proposals set out in the notice.Resolutions at the...

<div class="mfn-preamble"><p><strong>Scandinavian Real Heart AB (publ) held an Extraordinary General Meeting on December 16, 2025. All decisions were made in accordance with the proposals set out in the notice.</strong></p></div><div class="mfn-body"><p><strong>Resolutions at the General Meeting</strong></p><p><strong>Amendment of the Articles of Association</strong><br>The Annual General Meeting resolved to amend the Articles of Association, whereby the limits for the number of shares in the Articles of Association (§ 5) are changed to a minimum of 4,500,000 and a maximum of 18,000,000 and the limits for the share capital in the Articles of Association (§ 4) are changed to a minimum of SEK 22,545,000 and a maximum of SEK 90,180,000. The amendment is carried out in order to enable a rights issue of shares as set out below.</p><p><strong>Resolution on rights issue</strong><br>The Annual General Meeting resolved on a new issue of shares with preferential rights for existing shareholders. The issue is carried out in accordance with the terms and conditions set out in the notice, where each existing share entitles to one (1) subscription right entitling to subscription of one (1) new share. The total issue amount amounts to approximately SEK 70 million, of which SEK 49 million is guaranteed through subscription commitments and guarantee commitments. The subscription price amounts to SEK 14 per share and the issue comprises a maximum of 4,998,704 new shares.<br><strong>Complete terms and conditions</strong></p><p>The complete resolutions and terms and conditions for the issue are available on the company's website:<strong> </strong><a rel="noopener" href="https://realheart.se/preferential-rights-issue-realheart/">https://realheart.se/preferential-rights-issue-realheart/</a> <br></p></div><div class="mfn-footer mfn-contacts mfn-ddde9c982a0b"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Ina Laura Perkins, CEO<br>Phone: +46 (0) 70 406 49 21&nbsp;<br>E-mail: <a rel="noopener" href="mailto:inalaura.perkins@realheart.se">inalaura.perkins@realheart.se</a><br>Certified Adviser: Svensk Kapitalmarknadsgranskning AB, <a rel="noopener" href="http://www.skmg.se">www.skmg.se</a></p></div><div class="mfn-footer mfn-about mfn-0285b54ad9f5"><p><strong class="mfn-heading-1">About Us</strong><br>Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit <a rel="noopener" href="http://www.realheart.se">www.realheart.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/4a3d3a20-dea3-40fd-a96f-5d3167f14cfb/bulletin-from-the-extraordinary-general-meeting-in-scandinavian-real-heart-ab-publ-on-16-december-2025.pdf" class="mfn-generated mfn-primary">Bulletin from the Extraordinary General Meeting in Scandinavian Real Heart AB (publ) on 16 December 2025</a></p></div>

Bulletin from the Extraordinary General Meeting in Scandinavian Real Heart AB (publ) on 16 December 2025